Monte Rosa Therapeutics filings document a clinical-stage biotechnology company developing molecular glue degrader medicines and reporting as a Nasdaq-listed operating company. Its 8-K filings cover financial results, Regulation FD clinical disclosures, material-event updates and capital-structure matters tied to common stock and registration statements.
The company’s proxy materials disclose annual meeting proposals, director elections, auditor ratification and governance practices. Other filings address executive officer and principal accounting officer transitions, compensatory arrangements, shareholder voting matters, clinical program disclosures for MRT-8102 and MRT-2359, and risk areas associated with drug development, financing and public-company compliance.
Monte Rosa Therapeutics provides an in-depth overview of its business, risks, and drug pipeline focused on molecular glue degraders, or MGDs, in this annual report. The company remains pre-revenue from drug sales and highlights a history of significant operating losses with expectations of continued losses.
Monte Rosa is advancing three core clinical programs: MRT-6160 for immune-mediated diseases (out-licensed to Novartis), MRT-8102 for NLRP3/IL-1/IL-6-driven inflammatory diseases, and MRT-2359 for MYC-driven cancers such as metastatic castration-resistant prostate cancer. Early clinical data show deep target degradation, strong pharmacodynamic effects, and generally favorable safety profiles.
The company has entered major collaborations with Novartis and Roche that include substantial upfront payments and large potential milestone and royalty streams. As of June 30, 2025, the aggregate market value of common equity held by non-affiliates was $212 million, and 80,015,667 shares of common stock were outstanding as of March 2, 2026.
Monte Rosa Therapeutics reported fourth quarter and full-year 2025 results alongside major clinical and financing milestones. Collaboration revenue was $2.8 million in Q4 2025 versus $60.6 million a year earlier, and $123.7 million for 2025 versus $75.6 million in 2024. Full-year net loss improved to $38.6 million from $72.7 million despite higher R&D spending of $141.5 million.
Cash, cash equivalents, restricted cash and marketable securities were $382.1 million as of December 31, 2025. A follow-on equity offering in January 2026 raised approximately $345 million gross (about $323.8 million net), extending the company’s funding runway into 2029.
Clinically, NEK7-directed MGD MRT-8102 showed strong Phase 1 anti-inflammatory activity with CRP reductions of 85% and favorable safety in 88 treated participants, supporting multiple planned Phase 2 trials starting in 2026–2027. Oncology candidate MRT-2359 delivered a 100% PSA response rate in AR-mutant mCRPC patients in combination with enzalutamide, with a Phase 2 study with apalutamide planned for Q3 2026. Partnered VAV1-directed MGD MRT-6160 is progressing toward Novartis-led Phase 2 studies, backed by a collaboration that could yield up to $2.1 billion in milestones.
Monte Rosa Therapeutics Principal Accounting Officer Edmund Dunn reported an automatic sale of 139 shares of common stock. The shares were sold on March 4, 2026 at a price of $17.96 per share to cover tax withholding obligations triggered by the vesting of restricted stock units. According to the disclosure, these sales were automatic and not at Dunn’s discretion. After this tax-related transaction, he beneficially owned 22,554 shares of Monte Rosa Therapeutics common stock directly.
Monte Rosa Therapeutics President & CEO Markus Warmuth reported an open-market sale of 5,466 shares of common stock at a weighted average price of $17.9243 per share on March 2, 2026. The trades occurred between $17.50 and $18.46 under a pre-arranged Rule 10b5-1 trading plan adopted on May 14, 2025. After these transactions, he directly holds 613,471 shares of Monte Rosa Therapeutics common stock.
GLUE submitted a Rule 144 notice reporting proposed sales of its common stock traded on NASDAQ. The filing notes an RSU vest on 03/03/2026 tied to equity compensation and lists recent trades by Edmund Dunn: 1,039 shares on 01/05/2026 for $15,762.65, 25,164 shares on 02/27/2026 for $455,506.15, and 536 shares on 03/02/2026 for $9,380.
Monte Rosa Therapeutics principal accounting officer Edmund Dunn reported option exercises paired with share sales. On February 27 and March 2, 2026, he exercised stock options to acquire common shares at an exercise price of $13.41 per share.
He then sold a total of 25,700 common shares in open-market transactions, including a weighted-average sale price of $18.1015 per share for one block and $17.50 per share for another. After these trades, Dunn directly owned 22,693 Monte Rosa Therapeutics shares.
Form 144 filing reporting proposed sales and recent transactions by Markus Warmuth. The excerpt lists a proposed sale entry showing Common security lines and an RSU stock award granted 01/02/2025 with a related date 01/02/2026. The filing shows prior sales in the past three months with amounts 128372.00 and 153759.00 tied to Markus Warmuth, and an additional numeric line 97974.00 associated with a common security entry. The filing names Monte Rosa Therapeutics Inc and lists an address for Mr. Warmuth in Boston.
Morgan Stanley Smith Barney LLC Executive Financial Services filed a Form 144 disclosing the proposed sale of 536 common shares by means of a stock option exercise on 03/02/2026. The filing lists cash proceeds as the method of settlement.
The excerpt also reports recent open-market sales by Edmund Dunn of 25,164 shares for $455,506.15 on 02/27/2026 and 1,039 shares for $15,762.65 on 01/05/2026.
Issuer files a Form 144 reporting proposed sale of 25,164 common shares. The filing lists the transaction type as a Stock Option Exercise with a sale date of 02/27/2026. It also shows prior shares sold of 1,039 on 01/05/2026 for $15,762.65.
Monte Rosa Therapeutics Chief Medical Officer Filip Janku reported an open-market sale of company stock. On February 23, 2026, he sold 9,189 shares of common stock at an average price of $19.4973 per share and now directly owns 65,837 shares.